HIM
CEROW

HGC Investment Management’s CERo Therapeutics Warrants CEROW Stock Holding History

HGC Investment Management’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$4K – 324
2022
Q3 		$4K Sell
50,000
-50,000
-50% -$4.21K ﹤0.01% 324
2022
Q2 		$17K Buy
100,000
+50,000
+100% +$8.06K ﹤0.01% 368
2022
Q1 		$11K Buy
+50,000
New +$18.6K ﹤0.01% 325

Other funds holding CEROW

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

HGC Investment Management's CEROW Position: Q4 2022 in Review

HGC Investment Management sold out of CERo Therapeutics Warrants (CEROW) in Q4 2022, closing a stake of 50,000 shares — an estimated $4K sold.

HGC Investment Management first reported a position in CEROW in Q1 2022 and held it in 3 quarters. The position peaked at $17K in Q2 2022. 49 funds tracked by Wall St. Rank hold CEROW as of Q4 2022.

  • HGC Investment Management reported no remaining CERo Therapeutics Warrants position as of Q4 2022 after selling out during the quarter.
  • HGC Investment Management sold 50,000 CERo Therapeutics Warrants shares in Q4 2022, an estimated $4K.
  • HGC Investment Management first reported a position in CERo Therapeutics Warrants in Q1 2022 and held it in 3 quarters.
  • HGC Investment Management's CERo Therapeutics Warrants position peaked at $17K in Q2 2022.
  • 49 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2022.

Based on HGC Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.